Notably, recent cardiovascular outcome trials (CVOTs) assessing SGLT-2 inhibitors have shown improvements in renal and cardiovascular outcomes in patients with and without Type 2 Diabetes Mellitus (T2DM). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.